PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1988122-10 1991 HD-MTX (8 g/m2) therapy with 5-formyltetrahydrofolate "rescue" (stage III) was usually begun about seven weeks after start of chemotherapy, and the patients were followed for two to eight courses separated by three to eight weeks. Leucovorin 29-53 metaxin 1 Homo sapiens 3-6 8823478-10 1996 MTX levels exceeded levels that require leucovorin rescue. Leucovorin 40-50 metaxin 1 Homo sapiens 0-3 7838036-5 1995 MTX was given as an intravenous infusion in 24 h and serum concentrations were measured up to at least 72 h after the start of infusion by an enzyme immunoassay (TDX Abbot, Dallas, TX) in order to modulate folinic acid rescue. Leucovorin 206-218 metaxin 1 Homo sapiens 0-3 8040679-1 1994 PURPOSE: Following high-dose methotrexate (HD-MTX) treatment, delayed MTX elimination is an important problem because it necessitates increased leucovorin rescue and additional hospitalization for hydration and urinary alkalinization. Leucovorin 144-154 metaxin 1 Homo sapiens 46-49 8040679-1 1994 PURPOSE: Following high-dose methotrexate (HD-MTX) treatment, delayed MTX elimination is an important problem because it necessitates increased leucovorin rescue and additional hospitalization for hydration and urinary alkalinization. Leucovorin 144-154 metaxin 1 Homo sapiens 70-73 1589134-1 1992 High dose of methotrexate (HDMTX) with leucovorin rescue requires over-hydratation to avoid nephrotoxicity; nevertheless the relationship between hydratation and plasma MTX levels is unknown. Leucovorin 39-49 metaxin 1 Homo sapiens 29-32 34668443-7 2022 The three patients underwent multiple dialysis sessions, until MTX serum concentrations remained sufficiently low to be neutralized by leucovorin. Leucovorin 135-145 metaxin 1 Homo sapiens 63-66 3493731-1 1987 During the use of a therapeutic regimen of high-dose methotrexate (HD-MTX) with leucovorin rescue in two cases of osteogenic sarcoma and malignant lymphoma without central nervous system (CNS) involvement, serial EEG monitoring before and after MTX infusion was performed with special reference to occipital basic activity. Leucovorin 80-90 metaxin 1 Homo sapiens 70-73 3316519-4 1987 Despite a strong pharmacologic rationale and a vast clinical experience, HDMTX with leucovorin rescue has not been shown to be unequivocally superior to conventional doses of MTX in any clinical situation except, perhaps, for treatment of osteogenic sarcoma and childhood acute leukemia. Leucovorin 84-94 metaxin 1 Homo sapiens 75-78 34665710-4 2021 Thus, this study aimed to investigate the in vitro rescuing effect of different folates including folic acid (FA), 5-methyltetrahydrofolate (MTHF) and folinic acid (5-Formyltetrahydrofolic acid, FTHF) on MTX-treated trophoblast cells. Leucovorin 151-163 metaxin 1 Homo sapiens 204-207 34665710-4 2021 Thus, this study aimed to investigate the in vitro rescuing effect of different folates including folic acid (FA), 5-methyltetrahydrofolate (MTHF) and folinic acid (5-Formyltetrahydrofolic acid, FTHF) on MTX-treated trophoblast cells. Leucovorin 165-193 metaxin 1 Homo sapiens 204-207 3496173-10 1987 Since in vitro studies on metabolism of folinic acid might be of great interest in trying to assess the mechanism of action of the folates and the potential interaction of MTX and 7-OH-MTX in this mechanism via the metabolism, the chromatographic method we describe here has been adapted for the separation of all the potential intracellular monoglutamyl metabolites of folinic acid. Leucovorin 40-52 metaxin 1 Homo sapiens 172-175 3496173-10 1987 Since in vitro studies on metabolism of folinic acid might be of great interest in trying to assess the mechanism of action of the folates and the potential interaction of MTX and 7-OH-MTX in this mechanism via the metabolism, the chromatographic method we describe here has been adapted for the separation of all the potential intracellular monoglutamyl metabolites of folinic acid. Leucovorin 40-52 metaxin 1 Homo sapiens 185-188 3496173-10 1987 Since in vitro studies on metabolism of folinic acid might be of great interest in trying to assess the mechanism of action of the folates and the potential interaction of MTX and 7-OH-MTX in this mechanism via the metabolism, the chromatographic method we describe here has been adapted for the separation of all the potential intracellular monoglutamyl metabolites of folinic acid. Leucovorin 370-382 metaxin 1 Homo sapiens 185-188 3496173-1 1987 A reversed-phase HPLC method is described for the simultaneous determination of folinic acid, MTX, and their plasma metabolites 5-CH3-FH4 and 7-OH-MTX respectively. Leucovorin 80-92 metaxin 1 Homo sapiens 147-150 3548154-16 1986 They can be avoided by administering leucovorin 12 hours after giving MTX. Leucovorin 37-47 metaxin 1 Homo sapiens 70-73 18282-1 1977 Urinary alkalinization with oral sodium bicarbonate has decreased the incidence of acute nephrotoxicity and subsequent myelotoxicity in 18 adults receiving high-dose methotrexate with calcium leucovorin rescue (MTX-LCV) weekly in doses of 1-7.5 g/m2. Leucovorin 184-202 metaxin 1 Homo sapiens 211-214 3874720-4 1985 Differential leucovorin protection was observed for the chain-extended MTX analogue PT441. Leucovorin 13-23 metaxin 1 Homo sapiens 71-74 3874720-8 1985 In addition, the different patterns of relative leucovorin requirements for DDMP and MTX protection suggest that differential metabolism or catabolism of leucovorin does not account for differential protection. Leucovorin 48-58 metaxin 1 Homo sapiens 85-88 32998716-3 2020 We hypothesize that Leucovorin accumulates during consecutive courses, which might result in a lower MTX uptake. Leucovorin 20-30 metaxin 1 Homo sapiens 101-104 1082190-5 1975 Intermittent chemotherapy with MTX only was given by slow intravenous injection at doses of 3 to 4 mg/kg for 24-48 h followed from the 48th h by folinic acid treatment for 1-2 days. Leucovorin 145-157 metaxin 1 Homo sapiens 31-34 33218420-1 2020 OBJECTIVE: We describe our experience with serial uterine artery embolization (UAE) combined with standard weekly methotrexate and a eight-day methotrexate/folinic acid (MTX/FA) treatment regimen in the management of placenta accreta spectrum (PAS) disorder at 7 weeks of gestation. Leucovorin 156-168 metaxin 1 Homo sapiens 170-173 25537545-6 2014 Leucovorin rescue was performed after 36 hours of the MTX administration and its dose was adjusted according to the MTX plasma concentration at 48 hours. Leucovorin 0-10 metaxin 1 Homo sapiens 54-57 29994985-5 2018 An artificially elevated MTX level results in unnecessarily long folinic acid administration, which decreases the effectivity of MTX. Leucovorin 65-77 metaxin 1 Homo sapiens 25-28 29994985-5 2018 An artificially elevated MTX level results in unnecessarily long folinic acid administration, which decreases the effectivity of MTX. Leucovorin 65-77 metaxin 1 Homo sapiens 129-132 27249385-1 2015 BACKGROUND: The use of high dose of MTX in the treatment of the leukemia is actually better controlled by renal preparation, control of plasma concentrations and administration of folinic acid. Leucovorin 180-192 metaxin 1 Homo sapiens 36-39 25563323-1 2015 BACKGROUND: High-dose methotrexate (HD-MTX) with folinic acid (leucovorin) rescue is the gold standard therapy in the treatment of osteosarcoma. Leucovorin 49-61 metaxin 1 Homo sapiens 39-42 25537545-6 2014 Leucovorin rescue was performed after 36 hours of the MTX administration and its dose was adjusted according to the MTX plasma concentration at 48 hours. Leucovorin 0-10 metaxin 1 Homo sapiens 116-119 21423118-0 2012 Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Leucovorin 12-24 metaxin 1 Homo sapiens 122-125 22609886-0 2013 Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Leucovorin 0-12 metaxin 1 Homo sapiens 34-37 22609886-3 2013 Folinic acid (FA) may ameliorate MTX toxicity. Leucovorin 0-12 metaxin 1 Homo sapiens 33-36 21423118-6 2012 Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic SCT using MTX as GVHD prophylaxis. Leucovorin 9-21 metaxin 1 Homo sapiens 188-191 17921849-4 2007 CF/MTX index was used to determine the calcium folinate (CF) rescuing intensity and toxicity was evaluated according to World Health Organization criteria. Leucovorin 39-55 metaxin 1 Homo sapiens 3-6 21867621-2 2011 MTX plasma concentration was dynamically detected and evaluated so as to avoid or reduce the side effects of HD-MTX, and adjust the time and dosage of calcium folinate (CF) or carry out the plasma exchange as occasion requires. Leucovorin 151-167 metaxin 1 Homo sapiens 0-3 20699066-1 2010 After HD-MTX infusions, i.e. at a dose>1 g/m2, monitoring of serum MTX concentrations is a standard practice which helps reducing the incidence of toxicity in patients with decreased clearance by guiding dose adjustment of leucovorin. Leucovorin 226-236 metaxin 1 Homo sapiens 70-73 18622418-0 2008 Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Leucovorin 0-12 metaxin 1 Homo sapiens 38-41 18622418-2 2008 Folinic acid may be involved in the amelioration of MTX toxicity. Leucovorin 0-12 metaxin 1 Homo sapiens 52-55 18622418-4 2008 A survey was conducted in Australian and New Zealand transplant centres (n=22) regarding the use of folinic acid following MTX in the transplant setting. Leucovorin 100-112 metaxin 1 Homo sapiens 123-126 18266225-13 2008 Forty-nine percent of the MTX courses were treated with standard dose leucovorin while 49% required a dose escalation, the majority of which was to 20-30 mg po q6h. Leucovorin 70-80 metaxin 1 Homo sapiens 26-29 18266225-17 2008 Approximately half of the patients will require leucovorin dose modification based on serial monitoring of MTX levels. Leucovorin 48-58 metaxin 1 Homo sapiens 107-110 18510172-1 2008 Preoperative high-dose methotrexate (HD-MTX) with folinic acid (leucovorin) rescue is still a mainstay in the treatment of osteosarcoma. Leucovorin 50-62 metaxin 1 Homo sapiens 40-43 17195068-11 2007 The protocol involving two sampling times, 24 and 48 h after the beginning of infusion, allows precise and accurate determination of individual pharmacokinetic parameters and consequently, it was possible to predict the time at which the MTX concentration reached the predicted threshold (0.2 microM) below which the administration of folinic acid could be stopped. Leucovorin 335-347 metaxin 1 Homo sapiens 238-241 10740644-0 2000 [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report]. Leucovorin 88-98 metaxin 1 Homo sapiens 41-44 12792734-9 2003 We conclude that in spite of adequate hydration and urine alkalinization and the use of pharmacokinetically guided leucoverin rescue, delayed clearance of MTX may still occur and that its incidence is higher in older patients and during the first cycles of treatment. Leucovorin 115-125 metaxin 1 Homo sapiens 155-158 10740644-0 2000 [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report]. Leucovorin 100-102 metaxin 1 Homo sapiens 41-44 10520733-1 1999 High-dose methotrexate (HD-MTX) with leucovorin rescue is a component of therapy in children with acute lymphoblastic leukaemia. Leucovorin 37-47 metaxin 1 Homo sapiens 27-30